Top

Open Access 12-04-2024 | Enzalutamide | Review Article

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

Authors: Brandon W. Lennep, Jesse Mack, Srinivasu Poondru, Elizabeth Hood, Brooke D. Looney, Monique Williams, Judeth J. Bianco, Alicia K. Morgans

Published in: Drug Safety

Abstract

Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also shown to be a mild inhibitor of the efflux transporter P-glycoprotein in patients with prostate cancer. Enzalutamide is primarily metabolized by CYP3A4 and CYP2C8. The risk of enzalutamide drug interactions arises primarily when it is coadministered with other drugs that interact with these CYPs, including CYP3A4. In this review, we begin by providing an overview of enzalutamide including its dosing, use in special populations, pharmacokinetics, changes to its prescribing information, and potential for interaction with coadministered drugs. Enzalutamide interactions with drugs from a wide range of medication classes commonly prescribed to patients with prostate cancer are described, including oral androgen deprivation therapy, agents used to treat a range of cardiovascular diseases, antidiabetic drugs, antidepressants, anti-seizure medications, common urology medications, analgesics, proton pump inhibitors, immunosuppressants, and antigout drugs. Enzalutamide interactions with common vitamins and supplements are also briefly discussed. This review provides a resource for healthcare practitioners and patients that will help provide a basis for the understanding and management of enzalutamide drug–drug interactions to inform decision making, improve patient safety, and optimize drug efficacy.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer 2022. Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed 10 Apr 2023.

Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: epidemiology, pathology, and screening. Fed Pract. 2015;32(Suppl. 4):41S-44S.PubMedPubMedCentral

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377–85. https://doi.org/10.1093/annonc/mdx742.CrossRefPubMed

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. https://doi.org/10.1186/s12916-015-0322-7.CrossRefPubMedPubMedCentral

Astellas Inc. Highlights of prescribing information: XTANDI (enzalutamide) capsules, for oral use 2022. Available from: https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf. [Accessed 10 May 2023].

Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122–9. https://doi.org/10.1111/bcp.13425.CrossRefPubMed

European Medicines Agency. XTANDI (enzalutamide). Summary of product characteristics 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf. [Accessed 29 May 2022].

Drugs.com. Available from: https://www.drugs.com. [Accessed 5 Jan 2024].

10.

Lexicomp. Drug interactions. Available from: http://online.lexi.com. [Accessed 5 Jan 2024].

11.

Prescribers' Digital Reference. 2023. Available from: https://pdr.net/. [Accessed 5 Jan 2024].

12.

Tsoukalas N, Brito-Dellan N, Font C, Butler T, Rojas-Hernandez CM, Butler T, et al. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022;30(10):8559–73. https://doi.org/10.1007/s00520-022-07235-8.CrossRefPubMedPubMedCentral

13.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.CrossRefPubMed

14.

Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251–63. https://doi.org/10.1016/j.jacc.2010.11.024.CrossRefPubMed

15.

Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23). https://doi.org/10.3390/ijms222312808.

16.

Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119–37. https://doi.org/10.1146/annurev.med.56.082103.104724.CrossRefPubMed

17.

Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019;130:65–77. https://doi.org/10.1016/j.ejps.2019.01.024.CrossRefPubMed

18.

Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210–58. https://doi.org/10.2165/00003088-199732030-00004.CrossRefPubMed

19.

Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–91. https://doi.org/10.1126/science.286.5439.487.CrossRefPubMed

20.

International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028.CrossRef

21.

Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83(8):1112–26. https://doi.org/10.1016/j.bcp.2012.01.030.CrossRefPubMedPubMedCentral

22.

Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581–7. https://doi.org/10.1074/jbc.M010173200.CrossRefPubMed

23.

Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7(5):584–90. https://doi.org/10.1038/87912.CrossRefPubMed

24.

Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1(4):259–66. https://doi.org/10.1038/nrd753.CrossRefPubMed

25.

Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–22. https://doi.org/10.1200/JCO.22.00193.CrossRefPubMedPubMedCentral

26.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31. https://doi.org/10.1056/NEJMoa1903835.CrossRefPubMed

27.

Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. https://doi.org/10.1056/NEJMoa1207506.CrossRefPubMed

28.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

29.

Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453–65. https://doi.org/10.1056/NEJMoa2303974.CrossRefPubMed

30.

European Medicines Agency. Guideline on the investigation of drug interactions. 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 10 Apr 2023.

31.

Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46. https://doi.org/10.1016/S0140-6736(10)60172-9.CrossRefPubMedPubMedCentral

32.

Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J-S, Beddo V, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043–55. https://doi.org/10.1007/s40262-015-0271-5.CrossRefPubMedPubMedCentral

33.

Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt J-S, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–69. https://doi.org/10.1007/s40262-015-0283-1.CrossRefPubMedPubMedCentral

34.

US Food and Drug Administration. Center for Drug Evaluation and Research Application Number: 203415Orig1s000. Clin Pharmacol Biopharm Rev. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf. Accessed 28 Jun 2023.

35.

Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15(5):1131–42. https://doi.org/10.1111/cts.13229.CrossRefPubMedPubMedCentral

36.

Albermann N, Schmitz-Winnenthal FH, Z’Graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70(6):949–58. https://doi.org/10.1016/j.bcp.2005.06.018.CrossRefPubMed

37.

Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014;25(2):429–34. https://doi.org/10.1093/annonc/mdt571.CrossRefPubMed

38.

Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286–94. https://doi.org/10.1093/annonc/mdv542.CrossRefPubMed

39.

Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647–61. https://doi.org/10.1038/s41391-021-00328-1.CrossRefPubMedPubMedCentral

40.

Boujonnier F, Lemaitre F, Scailteux L-M. Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07453-0.CrossRefPubMed

41.

Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27. https://doi.org/10.1111/j.1528-1167.2012.03671.x.CrossRefPubMed

42.

Shore ND, Morgans AK, El-Haddad G, Srinivas S, Abramowitz M. Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams. Target Oncol. 2022;17(6):709–25. https://doi.org/10.1007/s11523-022-00925-7.CrossRefPubMedPubMedCentral

43.

Conde-Estevez D, Henriquez I, Munoz-Rodriguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2022;18(9):601–13. https://doi.org/10.1080/17425255.2022.2122812.CrossRefPubMed

44.

Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021;13:1758835921998586. https://doi.org/10.1177/1758835921998586.CrossRefPubMedPubMedCentral

45.

Myovant Sciences Inc. Highlights of prescribing information: Orgovyx (relugolix) tablets, for oral use 2023. Available from: https://www.orgovyx.com/content/pdfs/orgovyx-prescribing-information.pdf. Accessed 10 Apr 2023.

46.

Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96. https://doi.org/10.1056/NEJMoa2004325.CrossRefPubMed

47.

George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, et al. Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023;21(3):383-92.e2. https://doi.org/10.1016/j.clgc.2023.03.009.CrossRefPubMed

48.

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314. https://doi.org/10.1002/cncr.28509.CrossRefPubMed

49.

Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021;39(1):52–62. https://doi.org/10.1016/j.urolonc.2020.08.003.CrossRefPubMed

50.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128. https://doi.org/10.1016/S0140-6736(12)61728-0.CrossRefPubMedPubMedCentral

51.

Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov. 2020;19(5):333–52. https://doi.org/10.1038/s41573-020-0061-0.CrossRefPubMed

52.

Bellia A, Della-Morte D, Di Daniele N, Lauro D. Drug interactions of direct oral anticoagulants in elderly patients with cardiometabolic diseases. Curr Res Pharmacol Drug Discov. 2021;2: 100029. https://doi.org/10.1016/j.crphar.2021.100029.CrossRefPubMedPubMedCentral

53.

Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, Minematsu T. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn. 2023;50:365–76. https://doi.org/10.1007/s10928-023-09867-7.CrossRefPubMedPubMedCentral

54.

Boehringer Ingelheim Inc. Highlights of prescribing information: Pradaxa (dabigatran etexilate) capsules, for oral use 2021. Available from: https://content.boehringer-ingelheim.com/DAM/c669f898-0c4e-45a2-ba55-af1e011fdf63/pradaxa%20capsules-us-pi.pdf. Accessed 10 Apr 2023.

55.

Bristol-Myers Squibb Inc. Highlights of prescribing information: coumadin (warfarin sodium) tablets, for oral use 2019. Available from: https://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 10 Apr 2023.

56.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39. https://doi.org/10.1016/s0140-6736(96)09457-3.CrossRef

57.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30. https://doi.org/10.1001/jama.293.17.2126.CrossRefPubMed

58.

van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399–409. https://doi.org/10.1016/j.jacc.2008.12.055.CrossRefPubMed

59.

Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714–21. https://doi.org/10.1093/eurheartj/ehp275.CrossRefPubMed

60.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57. https://doi.org/10.1056/NEJMoa0904327.CrossRefPubMed

61.

Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136(20):1955–75. https://doi.org/10.1161/CIRCULATIONAHA.117.031164.CrossRefPubMed

62.

Shah MB. Inhibition of CYP2C8 by acyl glucuronides of gemfibrozil and clopidogrel: pharmacological significance, progress and challenges. Biomolecules. 2022. https://doi.org/10.3390/biom12091218.CrossRefPubMedPubMedCentral

63.

Sanofi Inc. Highlights of prescribing information: PLAVIX (clopidogrel tablets) for oral use 2022. Available from: https://products.sanofi.us/plavix/plavix.pdf. Accessed 10 Apr 2023.

64.

AstraZeneca Inc. Highlights of prescribing information: BRILINTA (ticagrelor) tablets, for oral use. 2022. Available from: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/565ceafd-fbe3-4573-9c39-19280af566ec/565ceafd-fbe3-4573-9c39-19280af566ec_viewable_rendition__v.pdf. Accessed 10 Apr 2023.

65.

Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257(5):399–414. https://doi.org/10.1111/j.1365-2796.2005.01477.x.CrossRefPubMed

66.

Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73. https://doi.org/10.1161/CIR.0b013e318235eb4d.CrossRefPubMed

67.

Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207–13. https://doi.org/10.1161/01.cir.101.2.207.CrossRefPubMed

68.

Parke-Davis Div of Pfizer Inc. Highlights of prescribing information: LIPITOR (atorvastin calcium) tablets, for oral use 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&type=display. Accessed 10 Apr 2023.

69.

Organon Inc. Highlights of prescribing information: ZOCOR (simvastatin) tablets, for oral use 2022. Available from: https://www.organon.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf. Accessed 10 Apr 2023.

70.

Lupin Inc. Lovastatin tablets USP 2021. Available from: https://www.lupin.com/US/wp-content/uploads/2020/12/pi-lovastatin-tabs-usp-1-2021.pdf. Accessed 10 Apr 2023.

71.

Novartis Inc. Lescol XL (fluvastatin) package insert. 2017. Available from: https://www.novartis.com/sg-en/sites/novartis_sg/files/LESCOL%20%2080mg%20PI%20Decl2017.SIN_.pdf. Accessed 10 Apr 2023.

72.

Lowe RN, Marrs JC, Saseen JJ. Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. Ther Adv Drug Saf. 2013;4(1):9–17. https://doi.org/10.1177/2042098612474293.CrossRefPubMedPubMedCentral

73.

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25. https://doi.org/10.1111/j.1472-8206.2004.00299.x.CrossRefPubMed

74.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60. https://doi.org/10.1016/s0002-9149(03)00530-7.CrossRefPubMed

75.

Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12):1230–8. https://doi.org/10.1016/j.jacc.2013.11.007.CrossRefPubMed

76.

Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405–12. https://doi.org/10.1001/archinte.162.4.405.CrossRefPubMed

77.

Pfizer Laboratories Div Pfizer Inc. Highlights of prescribing information: NORVASC (amlodipine besylate) tablets for oral administration 2019. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd6a2ca-40c2-485c-bc53-db1c652505ed&type=display. Accessed 10 Apr 2023.

78.

Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–20. https://doi.org/10.1161/01.cir.97.14.1411.CrossRefPubMed

79.

Leonetti G, Egan CG. Use of carvedilol in hypertension: an update. Vasc Health Risk Manag. 2012;8:307–22. https://doi.org/10.2147/VHRM.S31578.CrossRefPubMedPubMedCentral

80.

Lei M, Wu L, Terrar DA, Huang CL. Modernized classification of cardiac antiarrhythmic drugs. Circulation. 2018;138(17):1879–96. https://doi.org/10.1161/CIRCULATIONAHA.118.035455.CrossRefPubMed

81.

Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16(1):123–6. https://doi.org/10.1080/08998280.2003.11927893.CrossRefPubMedPubMedCentral

82.

Szema AM, Dang S, Li JC. Emerging novel therapies for heart failure. Clin Med Insights Cardiol. 2015;9(Suppl. 2):57–64. https://doi.org/10.4137/CMC.S29735.CrossRefPubMedPubMedCentral

83.

Zhang M, Zou Y, Li Y, Wang H, Sun W, Liu B. The history and mystery of sacubitril/valsartan: from clinical trial to the real world. Front Cardiovasc Med. 2023;10:1102521. https://doi.org/10.3389/fcvm.2023.1102521.CrossRefPubMedPubMedCentral

84.

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–72. https://doi.org/10.1038/s41569-020-0406-8.CrossRefPubMed

85.

Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail. 2014;16(2):143–50. https://doi.org/10.1111/ejhf.31.CrossRefPubMed

86.

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19.CrossRefPubMed

87.

Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, et al. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep. 2018;8(1):18063. https://doi.org/10.1038/s41598-018-36212-7.CrossRefPubMedPubMedCentral

88.

Dave DJ. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011;2(4):230–5. https://doi.org/10.4103/0976-500X.85934.CrossRefPubMedPubMedCentral

89.

Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416–27. https://doi.org/10.1111/jdi.12644.CrossRefPubMedPubMedCentral

90.

Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;32:150–7. https://doi.org/10.1093/jncimonographs/lgh031.CrossRef

91.

Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387–401. https://doi.org/10.3390/neurolint13030038.CrossRefPubMedPubMedCentral

92.

Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–85. https://doi.org/10.1081/clt-120037428.CrossRefPubMed

93.

van Haelst IM, van Klei WA, Doodeman HJ, Warnier MJ, De Bruin ML, Kalkman CJ, Egberts TC. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. J Clin Psychiatry. 2014;75(1):15–21. https://doi.org/10.4088/JCP.13m08397.CrossRefPubMed

94.

Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32–8. https://doi.org/10.1097/jcp.0b013e318160738e.CrossRefPubMed

95.

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/JU.0000000000000309.CrossRefPubMed

96.

Welk B, McClure JA. The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia. Eur Urol Open Sci. 2022;46:22–9. https://doi.org/10.1016/j.euros.2022.10.008.CrossRefPubMedPubMedCentral

97.

Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243–85. https://doi.org/10.2165/00003088-200342140-00004.CrossRefPubMed

98.

Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. https://doi.org/10.1016/j.eururo.2009.09.035.CrossRefPubMed

99.

Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–24. https://doi.org/10.1016/S0025-6196(11)60750-7.CrossRefPubMedPubMedCentral

100.

Detert Oude Weme SEH, Vervenne WL, Imhoz ALT, Cremers RGHM, van Berlo-van de Laar IFR, Jansman FGA, et al. Assessment of the pharmacokinetic interaction of enzalutamide with oxycodone in men with prostate cancer: the ENZYME study. Ann Oncol. 2022;33(Suppl._7):S713-42.

101.

Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37. https://doi.org/10.5009/gnl15502.CrossRefPubMed

102.

Covis Pharma Inc. Highlights of prescribing infomration: Prilosec (omeprazole magnesium) for delayed-release oral suspension 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b6761f84-53ac-4745-a8c8-1e5427d7e179&type=display. Accessed 30 Apr 2023.

103.

Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996;13(4):611–5. https://doi.org/10.1023/a:1016062508580.CrossRefPubMed

104.

Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014;31(1):22–32. https://doi.org/10.1016/j.trim.2014.05.002.CrossRefPubMed

105.

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60. https://doi.org/10.1002/acr.24180.CrossRefPubMedPubMedCentral

106.

Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22(12):2489–503. https://doi.org/10.1200/JCO.2004.08.182.CrossRefPubMed

107.

Venturella G, Ferraro V, Cirlincione F, Gargano ML. Medicinal mushrooms: bioactive compounds, use, and clinical trials. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22020634.CrossRefPubMedPubMedCentral

108.

National Cancer Institute. Prostate cancer, nutrition, and dietary supplements (PDQ) - health professional version. Available from: https://www.cancer.gov/about-cancer/treatment/cam/hp/prostate-supplements-pdq. Accessed 10 Apr 2023.

109.

Sternberg CN. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncol. 2019;15(13):1437–57. https://doi.org/10.2217/fon-2018-0940.CrossRefPubMed

110.

Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br J Clin Pharmacol. 2014;78(5):1122–34. https://doi.org/10.1111/bcp.12425.CrossRefPubMedPubMedCentral

Title: Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy
Authors: Brandon W. Lennep
Jesse Mack
Srinivasu Poondru
Elizabeth Hood
Brooke D. Looney
Monique Williams
Judeth J. Bianco
Alicia K. Morgans
Publication date: 12-04-2024
Publisher: Springer International Publishing
Keywords: Enzalutamide
Prostate Cancer
Prostate Cancer
Published in: Drug Safety
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-024-01415-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content